New interferon approved for MS. (Pharmacology Update).

Rebif, an interferon beta-1a product, was recently approved for use in the United States by the Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS). Until recently, Avonex was the only interferon beta-1a product approved for use in the United States

for the treatment of MS. The orphan drug status of Avonex prevented marketing of any similar product until 2003. However, the clinical superiority of Rebif over Avonex in a European and North American study was recognized by the FDA, and approval was granted on March 8, 2002. Rebif has been available in other countries, including Canada.

The frequency of exacerbations and the accumulation of physical disability are decreased with the use of Rebif in relapsing-remitting MS. Efficacy in chronic-progressive forms of the disease has not been established. Side effect profiles are similar to Avonex. A full-service program is offered through the manufacturer, Serrono, including delivery, insurance reimbursement, and patient support.